Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide in Proliferative Diabetic Retinopathy
NCT00170742Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2003
- Primary completion
- May 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Novartis. Primary endpoint: Regression of neovascularization. Started Dec 2003; status: terminated.
02
Drugs
octreotide
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT00170742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170742.